A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

BACKGROUND: The mutation in KRAS exon 2 is a validated biomarker of resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Several reports have confirmed associations of other RAS mutations with resistance to anti-EGFR therapy. However, the impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawazoe, Akihito, Shitara, Kohei, Fukuoka, Shota, Kuboki, Yasutoshi, Bando, Hideaki, Okamoto, Wataru, Kojima, Takashi, Fuse, Nozomu, Yamanaka, Takeharu, Doi, Toshihiko, Ohtsu, Atsushi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393591/
https://www.ncbi.nlm.nih.gov/pubmed/25886136
http://dx.doi.org/10.1186/s12885-015-1276-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393591/
https://www.ncbi.nlm.nih.gov/pubmed/25886136
http://dx.doi.org/10.1186/s12885-015-1276-z

Ejemplares similares